These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38836284)

  • 41. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor.
    Konta Y; Saito E; Sato K; Furuta K; Miyauchi K; Furukawa A; Sato H; Yamamoto T
    Intern Med; 2022 Nov; 61(21):3239-3243. PubMed ID: 35283386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Euglycemic Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter-2 Inhibitor Use and Coronary Angiography: A Case Report.
    VonTungeln CD; Al Bataineh M
    Cureus; 2024 Jan; 16(1):e52122. PubMed ID: 38344581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
    Shimada K; Kanasaki K; Kato M; Ogura Y; Takagaki Y; Monno I; Hirai T; Kitada M; Koya D
    J Diabetes Investig; 2022 Jun; 13(6):955-964. PubMed ID: 35098679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis.
    Barkas F; Ntekouan SF; Liberopoulos E; Filippatos T; Milionis H
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105708. PubMed ID: 33714073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.
    Obara K; Shirakami Y; Maruta A; Ideta T; Miyazaki T; Kochi T; Sakai H; Tanaka T; Seishima M; Shimizu M
    Oncotarget; 2017 Aug; 8(35):58353-58363. PubMed ID: 28938561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
    Shikata K; Ito S; Kashihara N; Nangaku M; Wada T; Okuda Y; Sawanobori T; Sugimoto K
    J Diabetes Investig; 2022 Jul; 13(7):1190-1202. PubMed ID: 35199478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-Glucose Cotransporter-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Orthotopic Heart Transplant in a Prediabetic Patient: A Case Report.
    Cha BM; Davoudi R; DiVita MC; Fan AM; Kamath MY
    Transplant Proc; 2021 Oct; 53(8):2636-2639. PubMed ID: 34531071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.
    Cavka L; Bencak Ferko U; Pitz N; Trpkovski Z; Lainscak M
    ESC Heart Fail; 2021 Aug; 8(4):2631-2636. PubMed ID: 34102028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.
    Jones NK; Costello HM; Monaghan MT; Stewart K; Binnie D; Marks J; Bailey MA; Culshaw GJ
    Exp Physiol; 2023 Mar; 108(3):480-490. PubMed ID: 36644793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
    Li N; Chen R; Liu K
    Clin Drug Investig; 2020 Nov; 40(11):991-1000. PubMed ID: 32725362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sodium-glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure.
    Kanaoka K; Iwanaga Y; Nakai M; Nishioka Y; Myojin T; Kubo S; Okada K; Noda T; Sakata Y; Miyamoto Y; Saito Y; Imamura T
    Eur Heart J Cardiovasc Pharmacother; 2023 Jul; 9(5):444-452. PubMed ID: 37173281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The initial glycemic variability is associated with early neurological deterioration in diabetic patients with acute ischemic stroke.
    Hui J; Zhang J; Mao X; Li Z; Li X; Wang F; Wang T; Yuan Q; Wang S; Pu M; Xi G
    Neurol Sci; 2018 Sep; 39(9):1571-1577. PubMed ID: 29869743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia.
    Sabe SA; Xu CM; Sabra M; Harris DD; Malhotra A; Aboulgheit A; Stanley M; Abid MR; Sellke FW
    J Am Heart Assoc; 2023 Jan; 12(1):e028623. PubMed ID: 36583437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
    Hayami T; Kato Y; Kamiya H; Kondo M; Naito E; Sugiura Y; Kojima C; Sato S; Yamada Y; Kasagi R; Ando T; Noda S; Nakai H; Takada E; Asano E; Motegi M; Watarai A; Kato K; Nakamura J
    J Diabetes Investig; 2015 Sep; 6(5):587-90. PubMed ID: 26417418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.